GRAIL, Inc.
Description
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
About
CEO
Mr. Robert P. Ragusa
Employees
1,360
Instrument type
Common Stock
Sector
Healthcare
Industry
Diagnostics & Research
MIC code
XNGS
Address
1525 O’Brien Drive, Menlo Park, CA 94025, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Error: Invalid Earnings JSON format.
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 0 | — | 0 |
| Average estimate | — | 0.00 | — | 0.00 |
| Low estimate | — | 0.00 | — | 0.00 |
| High estimate | — | 0.00 | — | 0.00 |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total reported revenue | 93.11M |
| Cost of revenue | 188.72M |
| Gross profit | -95.61M |
| Operating expense | |
| Research & development | 338.75M |
| Selling general and admin | 362.56M |
| Other operating expenses | — |
| Operating income | -796.92M |
| Non operating interest income | |
| Income | 7.95M |
| Expense | — |
| Other income expense | -718.67M |
| Pretax income | -1.51B |
| Tax provision | -223.98M |
| Net income | -1.28B |
| Basic EPS | -41.34 |
| Diluted EPS | -41.34 |
| Basic average shares | 31.05M |
| Diluted average shares | 31.05M |
| EBITDA | 80.25M |
| Net income from continuing op. | -1.47B |
| Minority interests | — |
| Preferred stock dividends | — |
Balance sheet
| 2023 | 2022 | 2019 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2019-12-31 |
| Total assets | 3.91B | 4.94B | 635.52M |
| Current assets | |||
| Cash | — | — | — |
| Cash equivalents | — | — | — |
| Cash and cash equivalents | 97.29M | 241.60M | 143.19M |
| Other short term investments | — | — | 401.16M |
| Accounts receivable | 16.86M | 15.35M | — |
| Other receivables | — | — | — |
| Inventory | 21.70M | 19.76M | — |
| Prepaid assets | 13.31M | 14.52M | 13.17M |
| Restricted cash | — | — | — |
| Assets held for sale | — | — | — |
| Hedging assets | — | — | — |
| Other current assets | 20.10M | 18.66M | 12.59M |
| Non current assets | |||
| Properties | 84.39M | 104.71M | 35.04M |
| Land and improvements | — | — | — |
| Machinery furniture equipment | 54.14M | 46.96M | 30.43M |
| Construction in progress | 7.97M | 10.65M | 215,000 |
| Leases | 58.44M | 55.41M | 21.93M |
| Accumulated depreciation | -35.55M | -19.00M | -28.15M |
| Goodwill | 4.47B | 5.93B | — |
| Investment properties | — | — | — |
| Financial assets | — | — | — |
| Intangible assets | 2.69B | 2.94B | — |
| Investments and advances | — | — | 13.93M |
| Other non current assets | 12.21M | 10.67M | 4.61M |
| Total liabilities | 267.63M | 291.83M | 1.85B |
| Current liabilities | |||
| Accounts payable | 18.85M | 15.19M | 5.88M |
| Accrued expenses | 32.32M | 26.91M | 16.70M |
| Short term debt | 14.81M | 13.34M | 4.60M |
| Deferred revenue | — | — | — |
| Tax payable | — | — | — |
| Pensions | 96.00M | 74.10M | 14.89M |
| Other current liabilities | 809,000 | 3.11M | 2.66M |
| Non current liabilities | |||
| Long term debt | 69.60M | 82.68M | 36.64M |
| Provision for risks and charges | — | — | — |
| Deferred liabilities | 32.92M | 71.08M | — |
| Derivative product liabilities | — | — | 349,000 |
| Other non current liabilities | 1.50M | 3.13M | 3.08M |
| Shareholders equity | |||
| Common stock | — | — | 138,000 |
| Retained earnings | -7.78B | -6.31B | -1.31B |
| Other shareholders equity | 1.07M | 894,000 | 2.47M |
| Total shareholders equity | 3.65B | 4.65B | -1.21B |
| Additional paid in capital | — | — | 90.50M |
| Treasury stock | — | — | — |
| Minority interest | — | — | — |
Cash flow statement
| 2023 | |
|---|---|
| Operating Activities | |
| Net Income | -1.47B |
| Depreciation | 158.70M |
| Deferred Taxes | -38.15M |
| Stock-Based Compensation | 97.24M |
| Other Non-Cash Items | -74.08M |
| Accounts Receivable | -1.38M |
| Accounts Payable | 2.89M |
| Other Assets & Liabilities | 4.77M |
| Operating Cash Flow | -1.32B |
| Investing Activities | |
| Capital Expenditures | -12.89M |
| Net Intangibles | — |
| Net Acquisitions | — |
| Purchase of Investments | — |
| Sale of Investments | — |
| Investing Cash Flow | -12.89M |
| Financing Activities | |
| Long-Term Debt Issuance | — |
| Long-Term Debt Payments | — |
| Other Financing Charges | 463.77M |
| Financing Cash Flow | 463.77M |
| Other Cash Details | |
| End Cash Position | 101.51M |
| Income Tax Paid | — |
| Interest Paid | — |
| Free Cash Flow | -608.69M |
Error: Invalid format in Holders JSON file.
Article
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer screening blood tests.
Jan 27, 2025
Article
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%
Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 index in recent trading.
Jan 22, 2025
Article
Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif. , Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology.
Jan 13, 2025
